Massive study to monitor lupus drug safety in millions of young women

NCT ID NCT07431775

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how young women of childbearing age use the lupus drug Saphnelo (anifrolumab) in real-world settings. It will track treatment patterns and gather safety information, particularly regarding pregnancy, by reviewing existing health records from millions of patients in the US and Europe. The goal is to fulfill a regulatory requirement to better understand the drug's use in this specific population.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.